295 research outputs found
Pairing correlation in the two- and three-leg Hubbard ladders --- Renormalization and quantum Monte Carlo studies
In order to shed light whether the `even-odd conjecture' (even numbers of
legs will superconduct accompanied by a spin gap while odd ones do not) for
correlated electrons in ladder systems, the pairing correlation is studied for
the Hubbard model on a two- and three-leg ladders. We have employed both the
weak-coupling renormalization group and the quantum Monte Carlo (QMC) method
for strong interactions. For the two-leg Hubbard ladder, a systematic QMC (with
a controlled level spacings) has detected an enhanced pairing correlation,
which is consistent with the weak-coupling prediction. We also calculate the
correlation functions in the three-leg Hubbard ladder and show that the
weak-coupling study predicts the dominant superconductivity, which refutes the
naive even-odd conjecture. A crucial point is a spin gap for only some of the
multiple spin modes is enough to make the ladder superconduct with a pairing
symmetry (d-like here) compatible with the gapped mode. A QMC study for the
three-leg ladder endorses the enhanced pairing correlation.Comment: 20 pages, RevTex, uses epsf.sty and multicol.st
Extended Aharonov-Bohm period analysis of strongly correlated electron systems
The `extended Aharonov-Bohm (AB) period' recently proposed by Kusakabe and
Aoki [J. Phys. Soc. Jpn (65), 2772 (1996)] is extensively studied numerically
for finite size systems of strongly correlated electrons. While the extended AB
period is the system length times the flux quantum for noninteracting systems,
we have found the existence of the boundary across which the period is halved
or another boundary into an even shorter period on the phase diagram for these
models. If we compare this result with the phase diagram predicted from the
Tomonaga-Luttinger theory, devised for low-energy physics, the halved period
(or shorter periods) has a one-to-one correspondence to the existence of the
pairing (phase separation or metal-insulator transition) in these models. We
have also found for the t-J model that the extended AB period does not change
across the integrable-nonintegrable boundary despite the totally different
level statistics.Comment: 26 pages, RevTex, 16 figures available on request from
[email protected], to be published in J. Phys. Soc. Jpn 66 No.
7(1997), We disscus the extended AB period of strongly correlated systems
more systematically by performing numerical calculation for the t-J-J' model
and the extended Hubbard model in addition to the 1D t-J model and the t-J
ladde
From Kondo Effect to Fermi Liquid
The Kondo effect has been playing an important role in strongly correlated
electon systems. The important point is that the magnetic impurity in metals is
a typical example of the Fermi liquid. In the system the local spin is
conserved in the ground state and continuity with respect to Coulomb repulsion
is satisfied. This nature is satisfied also in the periodic systems as far
as the systems remain as the Fermi liquid. This property of the Fermi liquid is
essential to understand the cuprate high-Tc superconductors (HTSC). On the
basis of the Fermi liquid theory we develop the transport theory such as the
resistivity and the Hall coefficient in strongly correlated electron systems,
such as HTSC, organic metals and heavy Fermion systems. The significant role of
the vertex corrections for total charge- and heat-currents on the transport
phenomena is explained. By taking the effect of the current vertex corrections
into account, various typical non-Fermi-liquid-like transport phenomena in
systems with strong magnetic and/or superconducting flucutations are explained
within the Fermi liquid theory.Comment: 14 pages, an article for the special edition of JPSJ "Kondo Effect --
40 Years after the Discovery
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
<p>Abstract</p> <p>Background</p> <p>We previously reported that survivin-2B, a splicing variant of survivin, was expressed in various types of tumors and that survivin-2B peptide might serve as a potent immunogenic cancer vaccine. The objective of this study was to examine the toxicity of and to <b>c</b>linically and immunologically evaluate survivin-2B peptide in a phase I clinical study for patients with advanced or recurrent breast cancer.</p> <p>Methods</p> <p>We set up two protocols. In the first protocol, 10 patients were vaccinated with escalating doses (0.1–1.0 mg) of survivin-2B peptide alone 4 times every 2 weeks. In the second protocol, 4 patients were vaccinated with the peptide at a dose of 1.0 mg mixed with IFA 4 times every 2 weeks.</p> <p>Results</p> <p>In the first protocol, no adverse events were observed during or after vaccination. In the second protocol, two patients had induration at the injection site. One patient had general malaise (grade 1), and another had general malaise (grade 1) and fever (grade 1). Peptide vaccination was well tolerated in all patients. In the first protocol, tumor marker levels increased in 8 patients, slightly decreased in 1 patient and were within the normal range during this clinical trial in 1 patient. With regard to tumor size, two patients were considered to have stable disease (SD). Immunologically, in 3 of the 10 patients (30%), an increase of the peptide-specific CTL frequency was detected. In the second protocol, an increase of the peptide-specific CTL frequency was detected in all 4 patients (100%), although there were no significant beneficial clinical responses. ELISPOT assay showed peptide-specific IFN-γ responses in 2 patients in whom the peptide-specific CTL frequency in tetramer staining also was increased in both protocols.</p> <p>Conclusion</p> <p>This phase I clinical study revealed that survivin-2B peptide vaccination was well tolerated. The vaccination with survivin-2B peptide mixed with IFA increased the frequency of peptide-specific CTL more effectively than vaccination with the peptide alone, although neither vaccination could induce efficient clinical responses. Considering the above, the addition of another effectual adjuvant such as a cytokine, heat shock protein, etc. to the vaccination with survivin-2B peptide mixed with IFA might induce improved immunological and clinical responses.</p
- …